Biotech Portfolio Strategies: A pharmaceutical strategy & portfolio analysis

Summary:

Pharmaceutical Strategy & Portfolio Analysis
For biotech companies, the decision to partner or launch on your own will define your long-term success. Historically, the decision to sell to a larger company for launch was the best strategy. Today, more biotech companies than ever are successfully launching on their own. What’s behind this trend and what’s driving their success?

In this on-demand webinar, Michael Kleinrock, of The IQVIA Institute for Human Data Science, will moderate a panel of launch and market access experts as they discuss how biotech companies have resolved some of their key challenges to enable launch success. Specific points of the discussion will include:

An assessment of the overall outlook for biotech companies
Changes in the landscape that enable more companies to launch
What differentiates better performing launches
How to determine your optimal strategy to maximize the launch
Questions that need to be addressed when deciding whether to launch or to partner
Specifics in negotiation tactics and strategic support questions that are being asked and prioritized.

After this discussion, you should walk away knowing:

Major drivers behind the rise in product launches from biotech companies.
Capabilities needed for launch success, and how to ensure you have them.
Different pricing and market access strategies that are impacting launch activities.

Originally Aired October 23, 2019

Presenters:

Michael Kleinrock

Research Director, IQVIA Institute for Human Data Science

Michael Kleinrock serves as research director for the IQVIA Institute for Human Data Science, setting the research agenda for the institute, leading the development of reports and projects focused on the current and future role of human data science in healthcare in the U.S. and globally. Each year, Michael leads the development of IQVIA perspectives included in reports focused on advancing understanding of health and the complex systems and markets around the world that deliver healthcare.

Adam Sohn

Vice President, Global Consulting

Adam Sohn, Vice President, Global Consulting at IQVIA, is responsible for developing and executing global product offerings. During his 22+ year healthcare career, Adam has specialized in commercial strategy and global policy development for the life sciences industry. Adam supports both small and large biopharmaceutical companies with improving access, funding, and commercialization of niche and blockbuster drugs.

David Wolter

Vice President, Consulting

David Wolter brings more than 15 years of management consulting experience to his position as Vice President at IQVIA. He leads the US Strategy and Portfolio Analysis team, assisting clients with a wide range of solutions including product valuation, analog analyses, user-friendly valuation models, and decision-analysis training.

Sarah Rickwood

Vice President, European Thought Leadership

Sarah Rickwood has 26 years’ experience as a consultant to the pharmaceutical industry, having worked in Accenture’s pharmaceutical strategy practice prior to joining IQVIA. She has an extremely wide experience of international pharmaceutical industry issues, having worked most of the world’s leading pharmaceutical companies on issues in the US, Europe, Japan, and leading emerging markets.